This strategic partnership designates IGI Laboratories as the developer and manufacturer of a family of prescription topical drug products owned by Medimetriks Pharmaceuticals. In addition, as part of this long term relationship, Medimetriks has appointed IGI as Medimetriks’ authorized generic distributor of certain products in this line.
Medimetriks expects to launch its new line of prescription topical brands during the second quarter of 2012. IGI Laboratories is expected to begin the authorized generic distribution of certain of those products shortly thereafter.
IGI’s chief executive officer, Charlie Moore, stated, “This marks a significant step for IGI Laboratories as it expands into a fully-integrated developer and manufacturer of prescription topical pharmaceuticals. This partnership provides IGI the opportunity to enhance our relationship with a strong brand marketer as well as providing marketing opportunities as the authorized generic. Further, it complements our key corporate initiative, to continue to file our own Abbreviated New Drug Applications (ANDAs) and to establish a presence in the generic pharmaceutical arena. We appreciate the confidence Medimetriks has shown in IGI.”